Publications

  1. RNA Disruption Assay (RDA) as a biomarker of pCR in NeoAdjuvant trastuzumab-treated HER2-positive breast cancer Toomey S, Eustace AJ, Pritzker, L.B.; Pritzker, K.P.H.; Fay J, O’Grady A, Cummins R, O’Connor D, Young, L, Kay E, O’Donovan N, Gallagher WM, Kalachand R, Crown J, Hennessy BT
    NCI J Natl Cancer Inst (2016) 108 (8) djw111, First published online July 4, 2016 , doi:10.1093/jnci/djw111
  2. RNA Disruption Assay (RDA) as a biomarker of pCR in NeoAdjuvant trastuzumab-treated HER2-positive breast cancer Trudeau, M. E.
    JNCI J Natl Cancer Inst (2016) 108 (8): djw105 First published online July 4, 2016, doi:10.1093/jnci/djw105
  3. RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines
    Pritzker, K.P.H.; Pritzker,L. B.; Generali, D.; Bottini, A.; Cappelletti, M. R.; Guo, B.; Parissenti, A. M.; Trudeau, M.E.
    BMC Cancer (2016) 16:146. Published online, Febrary 24, 2016
    DOI 10.1186/s12885-016-2197-1
  4. Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy
    Parissenti, A.M.; Guo, B.; Pritzker,L.B.; Pritzker, K. P. H.; Wang, X.; Zhu, M.; Shepherd, L.; Trudeau, M. A.
    Breast Cancer Research and Treatment DOI 10.1007/s10549-015-3498-9 Published online July 25,2015 August 2015, Volume153(Issue1) Page p.135To-144
  5. RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy
    Pritzker, K.P.H.; Pritzker,L. B.; Generali, D.; Bottini, A.; Cappelletti, M. R.; Guo, B.; Parissenti, A. M.; Trudeau, M.E.
    JNCI Monographs 2015 2015 (51): 76-80
    doi: 10.1093/jncimonographs/lgv015
  6. Novel anti-hormonal agent, AT-001, impairs androgen-independent prostate tumor growth by suppressing the relaxin signaling pathway
    Anton Neschadim, Laura B. Pritzker, Kenneth P.H. Pritzker, Donald R. Branch, Alastair J.S. Summerlee, John Trachtenberg, Joshua D. Silvertown
    Endocrine- Related Cancer 2014 21;3 459 -471 ERC-14-0088.R1
  7. Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the “biological window therapy
    Chiara Foroni, Carla Strina, Manuela Milani, Mariarosa Cappelletti, Claudia Fumarola, Mara Bonelli, Ramona Bertoni, Giuseppina Ferrero, Elena Takano, Daniele Andrei*, Sergio Venturini, Giulia Brugnol, Pier Giorgio Petronini, Roberto Giardini, Laura Pritzker, Kenneth Pritzker ,Amadeo Parissenti, Alfredo Berruti, Stephen B Fox, Alberto Bottini, Daniele Generali
    Breast Cancer Research and Treatment 2014, 144 113-121
  8. Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients
    Amadeo M. Parissenti, Judy-Anne W. Chapman, Harriette J. Kahn,
    Baoqing Guo, Lei Han, Patti O’Brien, Mark P. Clemons, Roberta Jong,
    Rebecca Dent, Barbara Fitzgerald, Kathleen I. Pritchard, Lois E. Shepherd,
    Maureen E. Trudeau
    Breast Cancer Research and Treatment 2010:119, 347-356

The Chemo Response Company